Abstract PO1-28-07: Neoadjuvant Docetaxel Plus Cisplatin Versus Docetaxel Plus Doxorubicin and Cyclophosphamide in Early-Stage Triple-Negative Breast Cancer (HNBC-001): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial
Cancer Research(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined